Eirik Malinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3022082/publications.pdf Version: 2024-02-01



FIDIK MALINEN

#	Article	lF	CITATIONS
1	Deep learning-based automatic delineation of anal cancer gross tumour volume: a multimodality comparison of CT, PET and MRI. Acta OncolÃ ³ gica, 2022, 61, 89-96.	0.8	2
2	Mucosa-sparing dose painting of head and neck cancer. Acta Oncológica, 2022, 61, 141-145.	0.8	1
3	Positron emission tomography guided dose painting by numbers of lung cancer: Alanine dosimetry in an anthropomorphic phantom. Physics and Imaging in Radiation Oncology, 2022, 21, 101-107.	1.2	1
4	Volumetric parameters from [<scp>¹⁸F</scp>] <scp>FDG PET</scp> / <scp>CT</scp> predicts survival in patients with highâ€grade gastroenteropancreatic neuroendocrine neoplasms. Journal of Neuroendocrinology, 2022, 34, .	1.2	12
5	Deep learning-based auto-delineation of gross tumour volumes and involved nodes in PET/CT images of head and neck cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2782-2792.	3.3	23
6	A comparison of methods for fully automatic segmentation of tumors and involved nodes in PET/CT of head and neck cancers. Physics in Medicine and Biology, 2021, 66, 065012.	1.6	26
7	Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncológica, 2021, 60, 921-930.	0.8	7
8	Repeatability of hypoxia dose painting by numbers based on EF5-PET in head and neck cancer. Acta Oncológica, 2021, 60, 1386-1391.	0.8	7
9	Predicting outcomes in anal cancer patients using multi-centre data and distributed learning – A proof-of-concept study. Radiotherapy and Oncology, 2021, 159, 183-189.	0.3	18
10	Spatially fractionated radiotherapy: tumor response modelling including immunomodulation. Physics in Medicine and Biology, 2021, 66, 175012.	1.6	3
11	Synthesis, radiosynthesis, and positron emission tomography neuroimaging using 5â€{ ¹⁸ F]fluoro‣â€amino suberate. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 6-14.	0.5	1
12	The FLUKA Monte Carlo code coupled with an OER model for biologically weighted dose calculations in proton therapy of hypoxic tumors. Physica Medica, 2020, 76, 166-172.	0.4	13
13	Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity. EBioMedicine, 2020, 57, 102841.	2.7	15
14	Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer. Radiotherapy and Oncology, 2020, 153, 114-121.	0.3	15
15	Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy. Clinical and Translational Radiation Oncology, 2020, 22, 15-21.	0.9	14
16	Microdosimetry with a 3D silicon on insulator (SOI) detector in a low energy proton beamline. Radiation Physics and Chemistry, 2020, 176, 109078.	1.4	8
17	Re-irradiation for recurrent rectal cancer – a single-center experience. Acta Oncológica, 2020, 59, 534-540.	0.8	7
18	Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer. Molecular Imaging and Biology, 2019, 21, 391-398.	1.3	4

#	Article	IF	CITATIONS
19	Influx rate of 18F-fluoroaminosuberic acid reflects cystine/glutamate antiporter expression in tumour xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2190-2198.	3.3	16
20	The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status. Radiotherapy and Oncology, 2019, 140, 54-61.	0.3	23
21	Anal cancer chemoradiotherapy outcome prediction using ¹⁸ F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. British Journal of Radiology, 2019, 92, 20181006.	1.0	23
22	Ultra-early changes in vascular parameters from dynamic contrast enhanced MRI of breast cancer xenografts following systemic therapy with doxorubicin and liver X receptor agonist. Cancer Imaging, 2019, 19, 88.	1.2	6
23	Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy. Advances in Radiation Oncology, 2018, 3, 130-138.	0.6	6
24	Dose painting for re-irradiation of head and neck cancer. Acta Oncológica, 2018, 57, 1693-1699.	0.8	16
25	Comparison of time curves from dynamic 18F-fluciclovine positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging for primary prostate carcinomas. Physics and Imaging in Radiation Oncology, 2018, 7, 51-57.	1.2	4
26	Dynamic TSPO-PET for assessing early effects of cerebral hypoxia and resuscitation in new born pigs. Nuclear Medicine and Biology, 2018, 66, 49-57.	0.3	6
27	Impact of dose escalation and adaptive radiotherapy for cervical cancers on tumour shrinkage—a modelling study. Physics in Medicine and Biology, 2017, 62, N107-N119.	1.6	5
28	Monte Carlo simulations of a low energy proton beamline for radiobiological experiments. Acta Oncológica, 2017, 56, 779-786.	0.8	24
29	Autodelineation of cervical cancers using multiparametric magnetic resonance imaging and machine learning. Acta Oncológica, 2017, 56, 806-812.	0.8	26
30	Patterns of local-regional recurrence after conformal and intensity-modulated radiotherapy for head and neck cancer. Radiation Oncology, 2017, 12, 87.	1.2	19
31	Dynamic contrast enhanced magnetic resonance imaging for hypoxia mapping and potential for brachytherapy targeting. Physics and Imaging in Radiation Oncology, 2017, 2, 1-6.	1.2	12
32	In Quest of the Alanine R3 Radical: Multivariate EPR Spectral Analyses of X-Irradiated Alanine in the Solid State. Journal of Physical Chemistry A, 2017, 121, 7139-7147.	1.1	10
33	A new method to assess pulmonary changes using ¹⁸ F-fluoro-2-deoxyglucose positron emission tomography for lung cancer patients following radiotherapy. Acta OncolA³gica, 2017, 56, 1597-1603.	0.8	6
34	Hypoxia in cervical cancer: from biology to imaging. Clinical and Translational Imaging, 2017, 5, 373-388.	1.1	40
35	Assessment of pulmonary 18 F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib. Clinical and Translational Radiation Oncology, 2017, 4, 57-63.	0.9	8
36	Bridging imaging and therapy: the role of medical physics in development of precision cancer care. Acta Oncológica, 2017, 56, 757-760.	0.8	2

#	Article	IF	CITATIONS
37	Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts. Molecular Imaging and Biology, 2017, 19, 271-279.	1.3	4
38	Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography. Radiation Oncology, 2017, 12, 147.	1.2	20
39	Validation of dose painting of lung tumours using alanine/EPR dosimetry. Physics in Medicine and Biology, 2016, 61, 2243-2254.	1.6	6
40	Cluster analysis of dynamic contrast enhanced MRI reveals tumor subregions related to locoregional relapse for cervical cancer patients. Acta Oncológica, 2016, 55, 1294-1298.	0.8	33
41	Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer. Clinical Cancer Research, 2016, 22, 4067-4076.	3.2	43
42	Short-course PET based simultaneous integrated boost for locally advanced cervical cancer. Radiation Oncology, 2016, 11, 39.	1.2	14
43	Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients. PLoS ONE, 2016, 11, e0156259.	1.1	28
44	Dose painting by numbers in a standard treatment planning system using inverted dose prescription maps. Acta Oncológica, 2015, 54, 1607-1613.	0.8	21
45	Variability of dynamic 18F-FDG-PET data in breast cancer xenografts. Acta Oncológica, 2015, 54, 1399-1407.	0.8	4
46	Dose or â€~LET' painting – What is optimal in particle therapy of hypoxic tumors?. Acta Oncológica, 2015, 54, 1614-1622.	0.8	32
47	Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts. Acta OncolÃ ³ gica, 2014, 53, 1086-1092.	0.8	4
48	Spatial dosimetric sensitivity of contouring uncertainties in gynecological 3D-based brachytherapy. Radiotherapy and Oncology, 2014, 113, 414-419.	0.3	6
49	Impact of PET reconstruction algorithm and threshold on dose painting of non-small cell lung cancer. Radiotherapy and Oncology, 2014, 113, 210-214.	0.3	15
50	Image guided therapy – Do we get the picture?. Acta Oncológica, 2014, 53, 3-5.	0.8	3
51	Arm and shoulder morbidity following surgery and radiotherapy for breast cancer. Acta Oncológica, 2014, 53, 521-529.	0.8	72
52	Classification of Dynamic Contrast Enhanced MR Images of Cervical Cancers Using Texture Analysis and Support Vector Machines. IEEE Transactions on Medical Imaging, 2014, 33, 1648-1656.	5.4	88
53	EPR Dosimetry in Clinical Applications. , 2014, , 509-538.		5
54	Abstract 2053: Dynamic 18F-FDG PET parameters variation in patient-derived breast cancer xenograft and correlation with outcome following treatment with cytotoxic agents. , 2014, , .		0

#	Article	IF	CITATIONS
55	Dynamic 18 F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts. Nuclear Medicine and Molecular Imaging, 2013, 47, 173-180.	0.6	7
56	Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. Radiotherapy and Oncology, 2013, 107, 117-122.	0.3	73
57	Long-term Cardiac Mortality After Hypofractionated Radiation Therapy in Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 337-343.	0.4	29
58	Dosimetric impact of interobserver variability in MRI-based delineation for cervical cancer brachytherapy. Radiotherapy and Oncology, 2013, 107, 13-19.	0.3	87
59	Intermittent and continuous imatinib in a human GIST xenograft model carrying <i>KIT</i> exon 17 resistance mutation D816H. Acta Oncológica, 2013, 52, 776-782.	0.8	13
60	Functional imaging to monitor vascular and metabolic response in canine head and neck tumors during fractionated radiotherapy. Acta Oncológica, 2013, 52, 1293-1299.	0.8	8
61	Biologic targets identified from dynamic18FDG-PET and implications for image-guided therapy. Acta Oncológica, 2013, 52, 1378-1383.	0.8	10
62	Quantitative dynamic ¹⁸ FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta Oncológica, 2013, 52, 1160-1167.	0.8	16
63	Dynamic ¹⁸ F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts. Acta Oncológica, 2013, 52, 1566-1572.	0.8	29
64	Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors. Acta Oncológica, 2012, 51, 603-609.	0.8	7
65	Dynamic Contrast-Enhanced MRI of Cervical Cancers: Temporal Percentile Screening of Contrast Enhancement Identifies Parameters for Prediction of Chemoradioresistance. International Journal of Radiation Oncology Biology Physics, 2012, 82, e485-e492.	0.4	36
66	Low dose hyper-radiosensitivity is eliminated during exposure to cycling hypoxia but returns after reoxygenation. International Journal of Radiation Biology, 2012, 88, 311-319.	1.0	19
67	Hypoxia-Induced Gene Expression in Chemoradioresistant Cervical Cancer Revealed by Dynamic Contrast-Enhanced MRI. Cancer Research, 2012, 72, 5285-5295.	0.4	128
68	Dynamic FDG PET for assessing early effects of cerebral hypoxia and resuscitation in new-born pigs. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 792-799.	3.3	10
69	Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers. Acta Oncológica, 2011, 50, 859-865.	0.8	19
70	Spatiotemporal analysis of tumor uptake patterns in dynamic18FDG-PET and dynamic contrast enhanced CT. Acta Oncológica, 2011, 50, 873-882.	0.8	12
71	Dynamic respiratory gated18FDG-PET of lung tumors – a feasibility study. Acta Oncológica, 2011, 50, 889-896.	0.8	6
72	Dosimetric verification of biologically adapted IMRT. Medical Physics, 2011, 38, 2586-2594.	1.6	1

#	Article	IF	CITATIONS
73	Review of the dose-to-water energy dependence of alanine and lithium formate EPR dosimeters and LiF TL-dosimeters – Comparison with Monte Carlo simulations. Radiation Measurements, 2011, 46, 945-951.	0.7	26
74	Characterization of lithium formate EPR dosimeters for high dose applications – Comparison with alanine. Radiation Measurements, 2011, 46, 213-218.	0.7	11
75	Adapting Biological Feedback in Radiotherapy. Seminars in Radiation Oncology, 2010, 20, 138-146.	1.0	10
76	Radical Formation in Lithium Formate EPR Dosimeters after Irradiation with Protons and Nitrogen Ions. Radiation Research, 2010, 174, 251-257.	0.7	12
77	Dosimetry of stereotactic radiosurgery using lithium formate EPR dosimeters. Physics in Medicine and Biology, 2010, 55, 2307-2316.	1.6	11
78	The energy dependence of lithium formate and alanine EPR dosimeters for medium energy x rays. Medical Physics, 2010, 37, 3569-3575.	1.6	42
79	Feasibility of contrast-enhanced cone-beam CT for target localization and treatment monitoring. Radiotherapy and Oncology, 2010, 97, 521-524.	0.3	6
80	Evaluation of adaptive radiotherapy of bladder cancer by image-based tumour control probability modelling. Acta Oncológica, 2010, 49, 1045-1051.	0.8	22
81	Influence of MLC leaf width on biologically adapted IMRT plans. Acta Oncológica, 2010, 49, 1116-1123.	0.8	15
82	Adaptive radiotherapy based on contrast enhanced cone beam CT imaging. Acta Oncológica, 2010, 49, 972-977.	0.8	13
83	Preclinical dynamic ¹⁸ F-FDG PET – tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncológica, 2010, 49, 914-921.	0.8	27
84	The Performance of Multileaf Collimators Evaluated by the Stripe Test. Medical Dosimetry, 2009, 34, 202-206.	0.4	5
85	Strategies for Biologic Image-Guided Dose Escalation: A Review. International Journal of Radiation Oncology Biology Physics, 2009, 73, 650-658.	0.4	90
86	DCEMRI of spontaneous canine tumors during fractionated radiotherapy: A pharmacokinetic analysis. Radiotherapy and Oncology, 2009, 93, 618-624.	0.3	10
87	MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy. Radiotherapy and Oncology, 2009, 93, 279-284.	0.3	28
88	Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncológica, 2008, 47, 1257-1264.	0.8	7
89	Optimal treatment margins for radiotherapy of prostate cancer based on interfraction imaging. Acta Oncológica, 2008, 47, 1373-1381.	0.8	11
90	DCEMRI monitoring of canine tumors during fractionated radiotherapy. Acta Oncológica, 2008, 47, 1249-1256.	0.8	12

#	Article	IF	CITATIONS
91	The energy dependence of lithium formate EPR dosimeters for clinical electron beams. Physics in Medicine and Biology, 2007, 52, 4361-4369.	1.6	13
92	Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Physics in Medicine and Biology, 2007, 52, 499-513.	1.6	77
93	Contralateral breast doses following radiotherapy of the breast and regional lymph nodes: Measurements and treatment planning calculations. Radiotherapy and Oncology, 2007, 82, 332-336.	0.3	15
94	On the parameter describing the generalised equivalent uniform dose (gEUD) for tumours. Physica Medica, 2007, 23, 100-106.	0.4	20
95	Radiotherapy Adapted to Spatial and Temporal Variability in Tumor Hypoxia. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1496-1504.	0.4	70
96	LET effects following neutron irradiation of lithium formate EPR dosimeters. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2006, 63, 861-869.	2.0	22
97	EPR dosimetry of radiotherapy photon beams in inhomogeneous media using alanine films. Physics in Medicine and Biology, 2006, 51, 6315-6328.	1.6	8
98	Adapting radiotherapy to hypoxic tumours. Physics in Medicine and Biology, 2006, 51, 4903-4921.	1.6	70
99	Formates and dithionates: sensitive EPR-dosimeter materials for radiation therapy. Applied Radiation and Isotopes, 2005, 62, 317-324.	0.7	68
100	Estimation of X-ray beam quality by electron paramagnetic resonance (EPR) spectroscopy. Applied Radiation and Isotopes, 2004, 60, 929-937.	0.7	6
101	Electron paramagnetic resonance (EPR) dosimetry using lithium formate in radiotherapy: comparison with thermoluminescence (TL) dosimetry using lithium fluoride rods. Physics in Medicine and Biology, 2004, 49, 4701-4715.	1.6	34
102	EPR dosimetric properties of formates. Applied Radiation and Isotopes, 2003, 59, 181-188.	0.7	70
103	Hole transfer in crystals of cytosine monohydrate: an EPR study. Physical Chemistry Chemical Physics, 2003, 5, 1665-1670.	1.3	18
104	Radical Formation in Pyrimidine Bases after X, Proton and α-Particle Irradiation. Radiation Research, 2003, 160, 186-197.	0.7	7
105	Alanine Radicals, Part 3: Properties of the Components Contributing to the EPR Spectrum of X-Irradiated Alanine Dosimeters. Radiation Research, 2003, 159, 23-32.	0.7	61
106	Alanine Radicals, Part 4: Relative Amounts of Radical Species in Alanine Dosimeters after Exposure to 6–19 MeV Electrons and 10 kV–15 MV Photons. Radiation Research, 2003, 159, 149-153.	0.7	30
107	Alanine Radicals. 2. The Composite Polycrystalline Alanine EPR Spectrum Studied by ENDOR, Thermal Annealing, and Spectrum Simulationsâ€. Journal of Physical Chemistry A, 2002, 106, 8971-8977.	1.1	76
108	The influence of autologous tumor fibroblasts on the radiosensitivity of squamous cell carcinoma megacolonies. International Journal of Radiation Oncology Biology Physics, 2001, 50, 229-237.	0.4	6

#	Article	IF	CITATIONS
109	Regrowth delay analysis of irradiated tumors in the curative dose region. International Journal of Radiation Oncology Biology Physics, 2000, 46, 173-177.	0.4	2
110	Principal component-based image segmentation: a new approach to outline in vitro cell colonies. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 0, , 1-13.	1.3	2